South Korea readies for COVID-19 vaccine with airport transport drill | Inquirer News

South Korea readies for COVID-19 vaccine with airport transport drill

/ 01:35 PM February 03, 2021

SEOUL. — South Korea’s President Moon Jae-in called on Wednesday for seamless preparations for coronavirus vaccinations, as a refrigerated van drove in convoy with several military and police escort cars in a drill at the capital’s airport.

Despite initial success in taming earlier outbreaks, South Korea is grappling with its third and largest wave of infections, which has fueled criticism that it was slow to secure vaccines for a population of 52 million.

But no exact date has been set for the arrival of vaccines and this month’s start of an inoculation campaign targeting about 50,000 frontline health workers and the elderly that aims to cover about 10 million high-risk people by July.

Article continues after this advertisement

Wednesday’s preparedness drill at the Incheon international airport, west of Seoul, mobilized special freezers and ran through scenarios such as a terror attack, theft and transport faults, military and police officials said.

FEATURED STORIES

“We need to accomplish our tasks in the actual process of transport, storage and distribution without any errors,” Moon said during the drill.

“Repetitive exercises are important to ensure there won’t be any trials and errors that have occurred overseas, including missing vaccines and cold chain problems.”

Article continues after this advertisement

The vans carried containers specially made for the Pfizer and Moderna vaccines that require ultra cold storage, by Korean Air, the nation’s largest airline.

Article continues after this advertisement

One container can carry up to 60,000 doses at temperatures of minus 18 Celsius (minus 0.4 F) for about 100 hours, an airline official said.

Article continues after this advertisement

Vaccine centers have been designated in 250 indoor gyms and community halls nationwide, and equipped with cold storage facilities.

South Korea has deals with Pfizer Inc, AstraZeneca, Johnson & Johnson’s Janssen and Moderna Inc, as well as the World Health Organization-backed global COVAX scheme.

Article continues after this advertisement

Pfizer vaccines for about 60,000 people and AstraZeneca products for 300,000 more could arrive this month via COVAX, authorities have said.

The Korea Disease Control and Prevention Agency reported 467 new cases by Tuesday, as numbers rebounded above 400 in four days, boosted by continuing cluster infections.

Authorities have extended by two weeks a requirement to observe social distancing, urging vigilance ahead of next week’s Lunar New Year holidays, when tens of millions of Koreans usually travel across the country.

If the situation improves, however, the government might ease some measures this weekend, including a restaurant curfew, health ministry official Yoon Tae-ho told a briefing.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

(Interactive graphic tracking global spread of coronavirus: https://graphics.reuters.com/world-coronavirus-tracker-and-maps)

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Coronavirus, COVID-19, South korea

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.